Once the link between NLRX1 and the development of IBD was established, several studies explored the feasibility of targeting NLRX1 in the treatment of IBD by testing a small molecule NLRX1 activator named NX-13 [57,58]. Here, NLRX1 is linked to inflammatory bowel disease.